PhRMA

Congress should make sure savings on medicines go to patients, not PBMs. https://lnkd.in/eg_x6As7

Antibiotic-resistant infections are directly associated with over 1.2 million deaths per year. Without intervention, the threat of antimicrobial resistance (AMR) will only continue to grow. Vaccines are our greatest tool against evolving public health threats like AMR. If rolled out for all 23 evaluated pathogens in recent [tag] World Health Organization research, vaccines could reduce the number of antibiotics needed by 22% every year, and save one-third of the hospital costs associated with AMR. #WAAW #AMR https://lnkd.in/g37jBnY9

As an industry, we’ve made incredible progress in transforming diabetes care over the past century. This #AmericanDiabetesMonth, we recognize the important role innovation plays in improving the health of patients living with the disease and understand the critical need for a policy environment that prioritizes affordable access to life-saving diabetes treatments. Hear more from PhRMA’s Senior Director of Public Affairs & Strategic Initiatives, Drew Voytal, MPA-HCA, who has lived with type 1 diabetes for most of his life:

The biopharmaceutical industry is projected to spend over $100 billion a year to bring new medicines to patients, but 4 in 10 patients still face issues accessing the treatments they need. On November 21, PhRMA’s Chief Operating Officer, Lori Reilly will participate in a WTOP News webinar about the barriers to medicines imposed by middlemen and the legislative action needed to protect patient access. Register to watch here: https://lnkd.in/epr9uKV6

Hear Samaritan Health Services President Andrew von Eschenbach M.D discuss the importance of regulatory policies that allow medicine research and development to thrive.

Today, 90% of prescriptions for medicines are filled with generics. CEO Stephen Ubl describes how the market supports ongoing innovation and lowers costs for patients.

A recent study from Health Affairs examines the impact of the Inflation Reduction Act’s prescription drug price setting on post-approval R&D, a critical driver in the fight against cancer. Did you know? For nearly 9 out of 10 (89%) approved cancer medicines, additional clinical trials were initiated after the initial approval to explore new uses. In fact, more than half of all cancer medicine indications were approved after that first FDA approval. This post-approval research is essential for unlocking new treatment options for patients.    Health Affairs’ findings add to the growing body of evidence detailing the IRA’s unintended consequences. We know what’s wrong with the law. Now lawmakers need to fix it. https://lnkd.in/gAq-P65A

Eli Lilly and Company CEO Dave Ricks explains the dangers of the current administration’s proposed march-in rights framework on the pharmaceutical industry’s ability to develop new cancer treatments and cures and deliver them to patients like those with pancreatic cancer. #PancreaticCancerAwarenessMonth

This #NationalFamilyCaregiversMonth is a moment to recognize the substantial toll that Alzheimer’s disease has on the loved ones of patients living with this devastating condition. Watch more from Eli Lilly and Company's Anne White & PhRMA's Lori Reilly: https://lnkd.in/eJMDwRfE. #ENDALZ

Vaccines are highly effective and safe tools for protecting our health, with a long history of saving lives and reducing health care costs. Our Chief Medical Officer Dr. Michael Ybarra, MD recently participated in the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices. See his key takeaways here about what was discussed: